FDA approves Journavx for moderate to severe acute pain
Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.
Journavx is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years.
“Professional associations, medical journal editors, the National Academy of Medicine and other leaders must speak out in defense of science and public health. Silence in this critical moment is the wrong choice.”
“Biosimilars are making more therapies more available for America’s patients, but too many government policies are slowing biosimilar development and adoption,” said Craig Burton, executive director of the Biosimilars Council.
New leadership position focuses on driving innovation, growth and service excellence.
Texas A&M pharmacist says the injectable drugs change lives with unprecedented health benefits
The selection is based on nine key attributes related to corporate reputation, including quality of products and services, innovation, community responsibility, social responsibility, and talent management.
The decision aims to strengthen WBA’s balance sheet by reducing debt and improving free cash flow.
AI and technology enable nationwide medication delivery, supporting communities and helping customers live better.
Calls for immediate freeze of Medicare Drug Price Negotiation to protect pharmacies and patients.
Clinical trials showed Ozempic slowed kidney disease progression and lowered risks of kidney failure and cardiovascular events.
Company raises fiscal year 2025 outlook.
According to Advocate, all 47 clinics inside Illinois Walgreens were staffed by one to two medical office assistants, along with "additional clinicians who support virtual care operations."
Free grocery delivery and a stipend for healthy youth activities help members save time and money this year,
Sirolimus oral solution is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged greater or equal to 13 years, receiving renal transplants.
Blended, patient-level datasets leveraging proprietary tokenization technology simplify data enrichment while adhering to privacy standards.
“NACDS thanks Congressman Krishnamoorthi for his consistent leadership on this issue of importance in his District, throughout Illinois, and across the nation."